MICROBA LIFE SCIENCES LIMITED - Announcements

Market Cap $82.85M Add to my watchlist

Healthcare

Microba Life Sciences Limited is an Australia-based precision microbiome company. The... Microba Life Sciences Limited is an Australia-based precision microbiome company. The Company is engaged in the discovery and development of therapeutics for major chronic diseases and delivers gut microbiome testing services globally to researchers, clinicians, and consumers. It offers various platforms, such as Analysis, Discovery, and Therapeutic. Through its analysis and discovery platforms, it identifies microbiome-derived therapeutics and diagnostic tools to advance medicine. Through its Analysis Platform, it generates a global databank of microbiome samples and associated metadata to develop new health solutions. Its Discovery Platform enables partners to access this databank for the data-driven discovery of product opportunities. Its therapeutic platform is a repeatable platform for microbial therapeutic leads. It also offers a product portfolio of gastrointestinal, vaginal, oral, and urinary microbiome testing, together with a targeted set of evidence-based formulations. More

Announcements

Filter Results

All Price Sensitive Only

MAP	Notification of cessation of securities - MAP		03/06/24	12.88KB	Share
MAP	Q3 FY24 Quarterly Investor Presentation	PRICE SENSITIVE	23/04/24	3.8MB	Share
MAP	Q3 FY24 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	23/04/24	415.6KB	Share
MAP	Details of Q3 FY24 Quarterly Report, Appendix 4C & Webinar		18/04/24	142.29KB	Share
MAP	Microba Launches Investor Hub for Investor Engagement		16/04/24	161.93KB	Share
MAP	Microba receives $6.08 million R&D Tax Incentive Refund	PRICE SENSITIVE	10/04/24	156.94KB	Share
MAP	Notification of cessation of securities - MAP		10/04/24	12.94KB	Share
MAP	Ceasing to be a substantial holder		05/04/24	217.69KB	Share
MAP	Application for quotation of securities - MAP		05/04/24	14.34KB	Share
MAP	Release of Restricted Securities		25/03/24	150.33KB	Share
MAP	MetaPanel Launch Investor Presentation	PRICE SENSITIVE	13/03/24	2.01MB	Share
MAP	MetaPanel Diagnostic Test Launched with Sonic Healthcare	PRICE SENSITIVE	13/03/24	252.04KB	Share
MAP	Change in substantial holding		04/03/24	270.91KB	Share
MAP	Appendix 4D & FY24 Interim Report	PRICE SENSITIVE	28/02/24	2.03MB	Share
MAP	Change in substantial holding		26/02/24	230.09KB	Share
MAP	Q2 FY24 Quarterly Investor Presentation	PRICE SENSITIVE	30/01/24	4.09MB	Share
MAP	Q2 FY24 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	30/01/24	381.9KB	Share
MAP	Details of Q2 FY24 Quarterly Report, Appendix 4C & Webinar		29/01/24	130.4KB	Share
MAP	Notification of cessation of securities - MAP		25/01/24	21.78KB	Share
MAP	Release of Restricted Securities		19/01/24	150.39KB	Share
MAP	Notification regarding unquoted securities - MAP		29/12/23	28.17KB	Share
MAP	Change of Director's Interest Notice - Jacqueline Fernley		29/12/23	261.62KB	Share
MAP	Successful IBD Phase I Clinical Trial	PRICE SENSITIVE	07/12/23	233.97KB	Share
MAP	Cleansing Notice		06/12/23	198.24KB	Share
MAP	Application for quotation of securities - MAP		06/12/23	24.98KB	Share
MAP	Completion of Acquisition of Invivo Clinical Limited		06/12/23	138.15KB	Share
MAP	Proposed issue of securities - MAP		04/12/23	25.31KB	Share
MAP	Proposed issue of securities - MAP		04/12/23	25.22KB	Share
MAP	Research Agreement Executed with IFF for Allergy Program	PRICE SENSITIVE	04/12/23	168.71KB	Share
MAP	Results of Annual General Meeting		30/11/23	219.28KB	Share
MAP	2023 AGM Presentations		30/11/23	3.31MB	Share
MAP	Change in substantial holding		29/11/23	870.26KB	Share
MAP	Change in substantial holding		28/11/23	271.63KB	Share
MAP	Listing Rule 6.22.2 Adjustment to Option Exercise Prices		28/11/23	140.19KB	Share
MAP	Autoimmune Stage 1 Screening Complete with Gingko Bioworks	PRICE SENSITIVE	28/11/23	4.5MB	Share
MAP	Application for quotation of securities - MAP		23/11/23	25.19KB	Share
MAP	Results of Retail Entitlement Offer	PRICE SENSITIVE	20/11/23	189.95KB	Share
MAP	MAP CEO presents at Bell Potter Healthcare Conference 2023		16/11/23	3.05MB	Share
MAP	Investor Presentation		06/11/23	4.22MB	Share
MAP	Ceasing to be a substantial holder		02/11/23	27.87KB	Share
MAP	Change in substantial holding		01/11/23	823.34KB	Share
MAP	Change in substantial holding		01/11/23	351.54KB	Share
MAP	Change of Director's Interest Notice - Richard Bund		31/10/23	173.6KB	Share
MAP	Change of Director's Interest Notice - Prof Ian Frazer		31/10/23	175.4KB	Share
MAP	Change of Director's Interest Notice - Pasquale Rombola		31/10/23	175.11KB	Share
MAP	Annual Report to Shareholders		30/10/23	4.13MB	Share
MAP	Letter to Shareholders, Notice of AGM & Proxy Form		30/10/23	767.03KB	Share
MAP	Application for quotation of securities - MAP		30/10/23	24.82KB	Share
MAP	Letter to Ineligible Shareholders		26/10/23	151.21KB	Share
MAP	Retail Offer opens and dispatch of Offer Booklet		26/10/23	5.87MB	Share
MAP	Cleansing Notice under sections 708AA(12) and 708A(9)		23/10/23	237.63KB	Share
MAP	Update - Proposed issue of securities - MAP		23/10/23	30.85KB	Share
MAP	Fully Underwritten A$20 million Entitlement Offer	PRICE SENSITIVE	23/10/23	291.83KB	Share
MAP	Cleansing Notice section 708AA(2)(f) & 708A(5)(e)		19/10/23	195.61KB	Share
MAP	Notification to Optionholders		19/10/23	176.21KB	Share
MAP	Excluded Information Notice		19/10/23	145.28KB	Share
MAP	Proposed issue of securities - MAP		19/10/23	30.22KB	Share
MAP	Application for quotation of securities - MAP		19/10/23	28.52KB	Share
MAP	Invivo Clinical Acquisition and Capital Raising Presentation	PRICE SENSITIVE	19/10/23	4.47MB	Share
MAP	Microba to acquire UK microbiome leader Invivo Clinical	PRICE SENSITIVE	19/10/23	301.67KB	Share
MAP	Q1 FY24 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	19/10/23	951.13KB	Share
MAP	Trading Halt	PRICE SENSITIVE	19/10/23	518.73KB	Share
MAP	Date of AGM and Closing Date for Director Nominations		12/10/23	127.5KB	Share
MAP	Appendix 4G		30/08/23	287.84KB	Share
MAP	Appendix 4E & Annual Report	PRICE SENSITIVE	30/08/23	4.14MB	Share
MAP	Corporate Governance Statement		30/08/23	240.41KB	Share
MAP	Microba Completes Dosing in Phase I IBD Clinical Trial		25/08/23	171.99KB	Share
MAP	Notification regarding unquoted securities - MAP		04/08/23	32.65KB	Share
MAP	Q4 FY23 Quarterly Investor Presentation	PRICE SENSITIVE	27/07/23	3.32MB	Share
MAP	Q4 FY23 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	27/07/23	405.64KB	Share
MAP	Details of Q4 FY23 Quarterly Report, Appendix 4C & Webinar		25/07/23	130.52KB	Share
MAP	Microba to Present at 17th Bioshares Biotech Summit		24/07/23	6.78MB	Share
MAP	Ceasing to be a substantial holder		07/07/23	176.7KB	Share
MAP	First Distribution Agreement Executed with Sonic Healthcare	PRICE SENSITIVE	05/07/23	185.75KB	Share
MAP	Notification of cessation of securities - MAP		30/06/23	21.78KB	Share
MAP	Microba Commences Phase I Clinical Trial for IBD Therapeutic	PRICE SENSITIVE	28/06/23	172.48KB	Share
MAP	MRFF Grant Awarded to QUT, In Collaboration With Microba	PRICE SENSITIVE	27/06/23	162.02KB	Share
MAP	Notification of cessation of securities - MAP		16/06/23	21.78KB	Share
MAP	Microba receives two AusIndustry Advanced Overseas Findings	PRICE SENSITIVE	14/06/23	130.98KB	Share
MAP	Appendix 3Z - Final Director's Interest Notice		14/06/23	212.37KB	Share
MAP	Director Resignation		06/06/23	128.31KB	Share
MAP	Application for quotation of securities - MAP		29/05/23	25.09KB	Share
MAP	Cleansing Notice		29/05/23	147.29KB	Share
MAP	Change in substantial holding - Tiga Trading Pty Ltd		12/05/23	178.35KB	Share
MAP	Change in substantial holding from TEK		12/05/23	221.1KB	Share
MAP	Cleansing Notice		03/05/23	147.93KB	Share
MAP	Application for quotation of securities - MAP		03/05/23	25.63KB	Share
MAP	Q3 FY23 Quarterly Investor Presentation	PRICE SENSITIVE	20/04/23	3.6MB	Share
MAP	Q3 FY23 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	20/04/23	459.84KB	Share
MAP	Details of Q3 FY23 Quarterly Report, Appendix 4C & Webinar		19/04/23	130.98KB	Share
MAP	Cleansing Notice		14/04/23	147.42KB	Share
MAP	Application for quotation of securities - MAP		14/04/23	25.1KB	Share
MAP	SYNLAB Contracts Signed in Poland, Hungary, Romania, Croatia	PRICE SENSITIVE	13/04/23	167.54KB	Share
MAP	Microba Receives Ethics Approval for Phase 1 Clinical Trial	PRICE SENSITIVE	29/03/23	170.02KB	Share
MAP	Release of Securities from Voluntary Escrow		28/03/23	128.08KB	Share
MAP	NWR Virtual Healthcare Conference Presentation		21/03/23	3.93MB	Share
MAP	Microba to present at NWR Virtual Investor Conference		16/03/23	128.55KB	Share
MAP	SYNLAB Agreements Signed in Turkiye and Czech Republic	PRICE SENSITIVE	02/03/23	164.09KB	Share
MAP	Microba Launches Next Generation Healthcare Testing	PRICE SENSITIVE	28/02/23	224KB	Share
MAP	H1 FY23 Interim Report	PRICE SENSITIVE	23/02/23	7.93MB	Share

MAP Notification of cessation of securities - MAP
03/06/24		12.88KB	Share
MAP Q3 FY24 Quarterly Investor Presentation
23/04/24	PRICE SENSITIVE	3.8MB	Share
MAP Q3 FY24 Quarterly Activities Report & Appendix 4C
23/04/24	PRICE SENSITIVE	415.6KB	Share
MAP Details of Q3 FY24 Quarterly Report, Appendix 4C & Webinar
18/04/24		142.29KB	Share
MAP Microba Launches Investor Hub for Investor Engagement
16/04/24		161.93KB	Share
MAP Microba receives $6.08 million R&D Tax Incentive Refund
10/04/24	PRICE SENSITIVE	156.94KB	Share
MAP Notification of cessation of securities - MAP
10/04/24		12.94KB	Share
MAP Ceasing to be a substantial holder
05/04/24		217.69KB	Share
MAP Application for quotation of securities - MAP
05/04/24		14.34KB	Share
MAP Release of Restricted Securities
25/03/24		150.33KB	Share
MAP MetaPanel Launch Investor Presentation
13/03/24	PRICE SENSITIVE	2.01MB	Share
MAP MetaPanel Diagnostic Test Launched with Sonic Healthcare
13/03/24	PRICE SENSITIVE	252.04KB	Share
MAP Change in substantial holding
04/03/24		270.91KB	Share
MAP Appendix 4D & FY24 Interim Report
28/02/24	PRICE SENSITIVE	2.03MB	Share
MAP Change in substantial holding
26/02/24		230.09KB	Share
MAP Q2 FY24 Quarterly Investor Presentation
30/01/24	PRICE SENSITIVE	4.09MB	Share
MAP Q2 FY24 Quarterly Activities Report & Appendix 4C
30/01/24	PRICE SENSITIVE	381.9KB	Share
MAP Details of Q2 FY24 Quarterly Report, Appendix 4C & Webinar
29/01/24		130.4KB	Share
MAP Notification of cessation of securities - MAP
25/01/24		21.78KB	Share
MAP Release of Restricted Securities
19/01/24		150.39KB	Share
MAP Notification regarding unquoted securities - MAP
29/12/23		28.17KB	Share
MAP Change of Director's Interest Notice - Jacqueline Fernley
29/12/23		261.62KB	Share
MAP Successful IBD Phase I Clinical Trial
07/12/23	PRICE SENSITIVE	233.97KB	Share
MAP Cleansing Notice
06/12/23		198.24KB	Share
MAP Application for quotation of securities - MAP
06/12/23		24.98KB	Share
MAP Completion of Acquisition of Invivo Clinical Limited
06/12/23		138.15KB	Share
MAP Proposed issue of securities - MAP
04/12/23		25.31KB	Share
MAP Proposed issue of securities - MAP
04/12/23		25.22KB	Share
MAP Research Agreement Executed with IFF for Allergy Program
04/12/23	PRICE SENSITIVE	168.71KB	Share
MAP Results of Annual General Meeting
30/11/23		219.28KB	Share
MAP 2023 AGM Presentations
30/11/23		3.31MB	Share
MAP Change in substantial holding
29/11/23		870.26KB	Share
MAP Change in substantial holding
28/11/23		271.63KB	Share
MAP Listing Rule 6.22.2 Adjustment to Option Exercise Prices
28/11/23		140.19KB	Share
MAP Autoimmune Stage 1 Screening Complete with Gingko Bioworks
28/11/23	PRICE SENSITIVE	4.5MB	Share
MAP Application for quotation of securities - MAP
23/11/23		25.19KB	Share
MAP Results of Retail Entitlement Offer
20/11/23	PRICE SENSITIVE	189.95KB	Share
MAP MAP CEO presents at Bell Potter Healthcare Conference 2023
16/11/23		3.05MB	Share
MAP Investor Presentation
06/11/23		4.22MB	Share
MAP Ceasing to be a substantial holder
02/11/23		27.87KB	Share
MAP Change in substantial holding
01/11/23		823.34KB	Share
MAP Change in substantial holding
01/11/23		351.54KB	Share
MAP Change of Director's Interest Notice - Richard Bund
31/10/23		173.6KB	Share
MAP Change of Director's Interest Notice - Prof Ian Frazer
31/10/23		175.4KB	Share
MAP Change of Director's Interest Notice - Pasquale Rombola
31/10/23		175.11KB	Share
MAP Annual Report to Shareholders
30/10/23		4.13MB	Share
MAP Letter to Shareholders, Notice of AGM & Proxy Form
30/10/23		767.03KB	Share
MAP Application for quotation of securities - MAP
30/10/23		24.82KB	Share
MAP Letter to Ineligible Shareholders
26/10/23		151.21KB	Share
MAP Retail Offer opens and dispatch of Offer Booklet
26/10/23		5.87MB	Share
MAP Cleansing Notice under sections 708AA(12) and 708A(9)
23/10/23		237.63KB	Share
MAP Update - Proposed issue of securities - MAP
23/10/23		30.85KB	Share
MAP Fully Underwritten A$20 million Entitlement Offer
23/10/23	PRICE SENSITIVE	291.83KB	Share
MAP Cleansing Notice section 708AA(2)(f) & 708A(5)(e)
19/10/23		195.61KB	Share
MAP Notification to Optionholders
19/10/23		176.21KB	Share
MAP Excluded Information Notice
19/10/23		145.28KB	Share
MAP Proposed issue of securities - MAP
19/10/23		30.22KB	Share
MAP Application for quotation of securities - MAP
19/10/23		28.52KB	Share
MAP Invivo Clinical Acquisition and Capital Raising Presentation
19/10/23	PRICE SENSITIVE	4.47MB	Share
MAP Microba to acquire UK microbiome leader Invivo Clinical
19/10/23	PRICE SENSITIVE	301.67KB	Share
MAP Q1 FY24 Quarterly Activities Report & Appendix 4C
19/10/23	PRICE SENSITIVE	951.13KB	Share
MAP Trading Halt
19/10/23	PRICE SENSITIVE	518.73KB	Share
MAP Date of AGM and Closing Date for Director Nominations
12/10/23		127.5KB	Share
MAP Appendix 4G
30/08/23		287.84KB	Share
MAP Appendix 4E & Annual Report
30/08/23	PRICE SENSITIVE	4.14MB	Share
MAP Corporate Governance Statement
30/08/23		240.41KB	Share
MAP Microba Completes Dosing in Phase I IBD Clinical Trial
25/08/23		171.99KB	Share
MAP Notification regarding unquoted securities - MAP
04/08/23		32.65KB	Share
MAP Q4 FY23 Quarterly Investor Presentation
27/07/23	PRICE SENSITIVE	3.32MB	Share
MAP Q4 FY23 Quarterly Activities Report & Appendix 4C
27/07/23	PRICE SENSITIVE	405.64KB	Share
MAP Details of Q4 FY23 Quarterly Report, Appendix 4C & Webinar
25/07/23		130.52KB	Share
MAP Microba to Present at 17th Bioshares Biotech Summit
24/07/23		6.78MB	Share
MAP Ceasing to be a substantial holder
07/07/23		176.7KB	Share
MAP First Distribution Agreement Executed with Sonic Healthcare
05/07/23	PRICE SENSITIVE	185.75KB	Share
MAP Notification of cessation of securities - MAP
30/06/23		21.78KB	Share
MAP Microba Commences Phase I Clinical Trial for IBD Therapeutic
28/06/23	PRICE SENSITIVE	172.48KB	Share
MAP MRFF Grant Awarded to QUT, In Collaboration With Microba
27/06/23	PRICE SENSITIVE	162.02KB	Share
MAP Notification of cessation of securities - MAP
16/06/23		21.78KB	Share
MAP Microba receives two AusIndustry Advanced Overseas Findings
14/06/23	PRICE SENSITIVE	130.98KB	Share
MAP Appendix 3Z - Final Director's Interest Notice
14/06/23		212.37KB	Share
MAP Director Resignation
06/06/23		128.31KB	Share
MAP Application for quotation of securities - MAP
29/05/23		25.09KB	Share
MAP Cleansing Notice
29/05/23		147.29KB	Share
MAP Change in substantial holding - Tiga Trading Pty Ltd
12/05/23		178.35KB	Share
MAP Change in substantial holding from TEK
12/05/23		221.1KB	Share
MAP Cleansing Notice
03/05/23		147.93KB	Share
MAP Application for quotation of securities - MAP
03/05/23		25.63KB	Share
MAP Q3 FY23 Quarterly Investor Presentation
20/04/23	PRICE SENSITIVE	3.6MB	Share
MAP Q3 FY23 Quarterly Activities Report & Appendix 4C
20/04/23	PRICE SENSITIVE	459.84KB	Share
MAP Details of Q3 FY23 Quarterly Report, Appendix 4C & Webinar
19/04/23		130.98KB	Share
MAP Cleansing Notice
14/04/23		147.42KB	Share
MAP Application for quotation of securities - MAP
14/04/23		25.1KB	Share
MAP SYNLAB Contracts Signed in Poland, Hungary, Romania, Croatia
13/04/23	PRICE SENSITIVE	167.54KB	Share
MAP Microba Receives Ethics Approval for Phase 1 Clinical Trial
29/03/23	PRICE SENSITIVE	170.02KB	Share
MAP Release of Securities from Voluntary Escrow
28/03/23		128.08KB	Share
MAP NWR Virtual Healthcare Conference Presentation
21/03/23		3.93MB	Share
MAP Microba to present at NWR Virtual Investor Conference
16/03/23		128.55KB	Share
MAP SYNLAB Agreements Signed in Turkiye and Czech Republic
02/03/23	PRICE SENSITIVE	164.09KB	Share
MAP Microba Launches Next Generation Healthcare Testing
28/02/23	PRICE SENSITIVE	224KB	Share
MAP H1 FY23 Interim Report
23/02/23	PRICE SENSITIVE	7.93MB	Share

REFRESH

1 2 3 4 5

(20min delay)
Last 18.5¢		Change 0.000(0.00%)		Mkt cap ! $82.85M

Open	High	Low	Value	Volume
18.5¢	18.5¢	18.5¢	$504	2.727K

Buyers (Bids)

No.	Vol.	Price($)
4	58557	17.5¢

Sellers (Offers)

Price($)	Vol.	No.
18.5¢	58890	3

View Market Depth

No.	Vol.	Price($)
4	58557	0.175
2	35882	0.170
1	50000	0.165
5	174019	0.160
2	83500	0.155

Price($)	Vol.	No.
0.185	58890	3
0.190	32793	3
0.195	32660	1
0.200	68338	3
0.205	25000	1

Last trade - 10.40am 19/06/2024 (20 minute delay)

MAP (ASX) Chart

MICROBA LIFE SCIENCES LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories